Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals

There is limited knowledge of the use of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) in sub-Saharan Africa. We prospectively evaluated individuals infected with HCV genotypes 1 to 5 in Addis Ababa, Ethiopia. Liver fibrosis was assessed by AST-platelet ratio index sco...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of tropical medicine and hygiene 2020-11, Vol.103 (5), p.2083-2084
Main Authors: Sultan, Amir, Bane, Abate, Braimoh, Grace, Debes, Jose D
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Ethiopia - epidemiology
Female
Genotype
Hepacivirus - classification
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Hepatitis C - virology
Humans
Interferon
Liver cirrhosis
Male
Middle Aged
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is limited knowledge of the use of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) in sub-Saharan Africa. We prospectively evaluated individuals infected with HCV genotypes 1 to 5 in Addis Ababa, Ethiopia. Liver fibrosis was assessed by AST-platelet ratio index score and cirrhosis by imaging and laboratory values. All 164 individuals completed treatment. The majority of patients had genotype 4 (76%), and 19% of participants showed evidence of cirrhosis. Sustained virologic response (SVR) across all genotypes was 98.8%. In those with cirrhosis, SVR was 93.5% and in non-cirrhotics 100%. Our study demonstrates broad genotype successful treatment of HCV with DAAs in sub-Saharan Africa, demonstrating the feasibility of HCV elimination in resource-limited settings.
ISSN:0002-9637
1476-1645
DOI:10.4269/ajtmh.20-0367